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Abstract
Objective Cutaneous squamous cell carcinoma (cSCC) is one of the most prevalent non-melanoma skin cancers worldwide.
While usually treatable, patients with high-risk or advanced disease have few treatment options and limited resources available.
This review assesses what online information resources are available to patients and their families about either high-risk or
advanced cSCC.
Methods Searches were run, via Google, using 8 terms such as ‘advanced cutaneous squamous cell carcinoma patient informa-
tion’. Advertisements were removed and the first 3 pages/30 results from each search were screened for duplicates and then
against eligibility criteria. Websites needed to have been updated within the past 5 years, be freely accessible, designed specif-
ically for patients and refer to the advanced disease or high-risk setting. Remaining results were assessed using the DISCERN
tool.
Results Of the final 240 results, 121 were duplicates and 104 were ineligible. The remaining 15 sources were predominantly
aimed at American audiences, used variable terminology and revealed differing treatment pathways. Only 3 sites were deemed as
‘high’-quality information sources.
Conclusion There is a lack of accessible online information on high-risk or advanced cSCC for patients. What is available is often
too scientific or clinical and lacks clarity about the disease and treatment options.
Practice Implications Further work is needed to improve the integrity and accessibility of online sources and to signpost patients
to the most reliable information. This should include elements of patient led research, clinical education and information
development.
Keywords Cancer . Internet . Online information . Patient education . Skin cancer . Squamous cell carcinoma
Introduction
Non-melanoma skin cancer (NMSC) is one of the most prom-
inent cancers globally. Under that classification, cutaneous
squamous cell carcinoma (cSCC) is the second most common
skin cancer [1, 2]. While rates of skin cancer are increasing,
cSCC in particular is growing with an anticipated increase
amongst 30–39-year-olds [3–5]. Over 95% of patients will
be cured of the disease following surgery, with or without
radiotherapy [6, 7]. However, the remaining proportion will
progress to advanced disease, known as advanced cSCC.
While this is a smaller group of patients, survival drastically
reduces to a median of 2 years [8], leaving advanced cSCC as
the second most common cause of skin cancer death after
melanoma [3]. Some of the best indicators that a patient is
more likely to be at ‘high risk’ of progression are disease
location and previous local recurrence, but further genomic
markers are being developed [9].
Within the advanced disease setting, there are anxieties
about further treatment possibilities and survival. The care
pathway for cSCC is fairly straightforward; however, treat-
ments in the advanced setting are limited, with some evidence
for disease control using systemic therapies and EGFR inhib-
itors. Following recent treatment advancements, PD-1 inhibi-
tors such as cemiplimab have been authorized for this disease
group with further investigations ongoing into other
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immunotherapy options [6]. Additionally, patients may face
concerns over the impact of surgical scars and treatment,
along with the appearance of the diseased area [10]. As a high
proportion of these cancers appear on the head and neck, there
is an increase in anxiety, body image concerns and embarrass-
ment [5, 11]. Although this is a smaller group of patients, this
burden indicates a need for clear signposting towards support
and resources.
These information needs are one of the most unmet areas of
the cancer experience [12]. Within the broader NMSC setting,
research has shown that patients are often unsatisfied with
information provision, leading to greater dissatisfaction and
poorer rates of health related quality of life (HRQoL) [13].
There is a lack of research about this dedicated to the ad-
vanced cSCC cohort; however, guidelines stipulate that these
patients, or those at high risk, should be provided with infor-
mation about the disease with access to a multidisciplinary
palliative team [14]. Unfortunately, this group of patients is
not often offered appropriate psychosocial support or even a
clear pathway for treatment [15, 16].
Faced with a dearth of information from the clinical team,
patients will seek additional information sources about their
condition, including conducting online searches [12].
Estimates range from 16 to 69% of people with cancer using
the Internet for information [17]. This then raises concerns
about how reliable and consistent information is, further
compounded by low population levels of health literacy
[17–19]. Good quality information can help inform and em-
power patients; however, when that material differs from that
relayed by the clinical team, the patient may feel less satisfied
with their treatment [18, 19].
In this paper, we review the online platforms available to
patients when searching for information about high-risk or
advanced cSCC. Terms were selected as representative of
what patients may look for when going online for this
purpose.
Methods
Our primary aim was to identify the scope of online resources
available to individuals searching for information about ad-
vanced or high-risk cSCC. A secondary aim was to assess the
quality of the resources found.
We carried out online searches using eight terms: ‘ad-
vanced cutaneous squamous cell carcinoma’, ‘advanced
cutaneous squamous cell carcinoma patient information’,
‘high risk cutaneous squamous cell carcinoma’, ‘high risk
cutaneous squamous cell carcinoma patient information’,
‘squamous cell carcinoma’, ‘squamous cell carcinoma pa-
tient information’, ‘skin cancer’ and ‘skin cancer patient
information’. High-risk and advanced terms were separat-
ed out to reflect the different needs of these patient
groups. We included the terms ‘squamous cell carcinoma’
and ‘skin cancer’ as terminology can often be muddled or
confusing for patients. We planned to search specific
websites namely the British Skin Foundation, Cancer
Research UK (CRUK) and Macmillan for relevant
patient-related information. We included this to capture
the two main pathways patients might utilize, either using
a search engine or going directly to specific, well known,
websites.
Guidelines for conducting the review were documented
and agreed to by the research team prior to conducting the
searches. This guidance was modelled on methods used by
Weeks et al. [20]. Searches were run using Google and the
top 30 results, or first three pages, of each were retained.
Google was selected for its popularity and general accessibil-
ity. Typically, the first few results or the first page of searches
is used by individuals looking for information [21]. We ex-
tended beyond this to ensure we had a wider understanding of
what was available. Advertisements and sponsored results
were documented but removed from the main searches due
to the variability that can occur based on geography, demo-
graphics and Internet search history.
Each search was run on its own separate day between 16
June and 5 August 2020. Internet history was cleared prior to
each search to avoid confounding results from previous
browsing. The top 30 search results were entered onto an
Excel spreadsheet with corresponding name, URL and search
position. This was then verified by a second researcher who
ran the same term, using Google, on the day of the original
search. We aimed to achieve an 85% agreement of sites pres-
ent in both the original search and validation. We also docu-
mented any changes to ordering.
Once searches were complete, they were screened for du-
plicate entries. A site was considered a duplicate if a URL
pointed to the same page, or suite of information, as a previous
result, or was a secondary repository for the information. For
example, a ResearchGate finding would be considered a du-
plicate to a link for an academic publication. Similarly, a link
to a ‘signs and symptoms’ page would be considered a dupli-
cate to a ‘treatment pathway’ page hosted by the same
organization.
The remaining entries were screened against inclusion and
exclusion criteria. Our inclusion criteria for this project were
that sources should be charitable or health-based online re-
sources for patients and the public, with a focus on either
advanced or high-risk cSCC. Sites were excluded if they did
not feature the advanced or high-risk disease setting or were
older than 5 years, personal blogs or websites, not available in
English, clinical or academic materials or behind a log in or
paywall.
These processes had a 10% verification by a second re-
searcher to ensure duplicates were marked appropriately and
that there was an agreement with inclusion/exclusion.
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Those results that met the inclusion criteria were then
assessed against the DISCERN tool [22]. This measurement
is for individuals to assess the reliability of a health-based
publication. It is a standalone tool so does not require fact-
checking of the information. Instead, each publication is
assessed via 16 questions around areas which are deemed
important when considering treatment options, for example
shared decision-making. These were completed by one re-
searcher with 50% verification by another to ensure reliability.
As this project did not require human participants, no eth-
ical approval was sought.
Results
Across the eight search terms, there were a total of 240 results.
Of these, 121 were duplicate items and 104 were excluded,
leaving a final sample of 15 webpages.
The majority of excluded pages were classified as academ-
ic or clinical resources. This was particularly true in connec-
tion with the first four, more specific, search terms (‘advanced
cutaneous squamous cell carcinoma’, ‘advanced cutaneous
squamous cell carcinoma patient information’, ‘high risk cu-
taneous squamous cell carcinoma’ and ‘high risk cutaneous
squamous cell carcinoma patient information’). In compari-
son, sites rejected in searches 5-8 (‘squamous cell carcinoma’,
‘squamous cell carcinoma patient information’ ‘skin cancer’
and ‘skin cancer patient information’) were done so because
of their lack of information about the advanced or high-risk
setting. Returns were often rejected for more than one criterion
with the overall proportions as follows: 61.5%were clinical or
academic, 35.6% did not have information on the advanced
setting, 13.5% were not updated within 5 years and 10.6%
were behind a paywall or required login details. The search
results for terms 5–8 included the more well-known charitable
websites, and therefore, we did not need to take the planned
additional step of a focused review.
Within the search returns, there was a 96.25% agreement
between the two researchers conducting the searches, which
translated into 9 differing results. The range of agreement
within searches was 87.67–100%. This variability was more
present within the broader search terms (searches 5–8), which
also featured additional changes to ordering.
The final 15 results (Table 1) composed of six (40%) char-
itable or health-based organizations, e.g. Macmillan [23–28];
five (33.3%) hospital-based pages, e.g. the Mayo Clinic
[29–33]; and four (26.7%) online resources, e.g. Wikipedia
[34–37]. Sites were predominantly aimed at American audi-
ences (66.7%) [23–25, 27, 29–32, 34, 35] with only three UK
specific pages (20%) [26, 28, 33].
Most results came through multiple times across the vari-
ous search terms; however, pages such as the American
Cancer Society [27], DermNet NZ [36] and the Skin Cancer
Foundation [24] had broad coverage irrespective of the spec-
ificity of the search term.
The included results varied in their use of ‘advanced’, ‘met-
astatic’ or ‘high risk’ language. There were 11 sites (73.3%)
that used the terminology of advanced disease [23–25, 27, 29,
30, 32–36] and four that used ‘high risk’ (26.7%) [29, 30, 36,
37]. Two sites did not use any terminology (13.3%) [26, 28].
Sometimes, these words were not explicitly used, for example
metastatic disease was characterized by the word ‘spread’
[31]. More often, these terms were used without a clear defi-
nition of what they meant.
There were discrepancies in how sites referred to diagnosis
and treatment pathways; some did not specify who might be
involved in care [25, 34, 37], some started with a physician or
general practitioner (GP) and then outlined wider specialists
who may be involved, such as a dermatologist [26, 28], while
others gave further details on a multidisciplinary team (MDT)
including supportive and palliative care [23, 24, 27, 29–33,
35, 36].
There was further variability in the treatments men-
tioned. Following the advent of cemiplimab in 2018, six
pages mentioned it specifically (40%) [23–25, 34–36],
with another two discussing immunotherapy more broadly
(13.3%) [27, 31]. None of the UK specific websites talked
about immunotherapy. Five of the webpages discussed
participating in clinical trials (33.3%) [25, 26, 29, 30,
32]. Most pages included more comprehensive coverage
of surgical techniques, relevant to patients with or without
advanced or high-risk disease.
Of the 15 DISCERN scores, four sites were rated as
‘low’ (26.7%) [24, 29, 30, 33], eight were rated as ‘mod-
erate’ (53.3%) [23, 25, 26, 28, 31, 32, 35, 37] and three
were rated as ‘high’ (20%) [27, 34, 36] (Table 2). There
were notable inconsistencies across the pages. While
some emphasized the ability, and the importance, of
shared decision-making, others did not explicitly encour-
age a discussion between patient and physician. While no
website favored one treatment over another, some did not
include side effects to treatment or even explicitly name
the benefits. Notably absent from all those but the highest
scoring pages was a discussion about the impact on qual-
ity of life from treatment, including the option of not
having treatment. Similarly, those pages that scored lower
did not discuss any areas of uncertainty.
Outside of the 240 results, there were an additional 88
advertisements, some of which were duplicated either as
repeat ads (53/60.2%) or within the main search results
without being promoted. These ads included cancer cen-
ters, cancer charities (such as the Teenage Cancer Trust),
private physician pages and other health-based websites.
Some of this information was pertinent to treatment for
melanoma or head and neck cancer, an overlap often seen































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 DISCERN quality assessments
Resource name Author Overall
DISCERN
score
Higher scoring points Lower scoring points




Moderate • Clear references
• Relevant information
•Discussion of different treatment types
• Lacking discussion about shared
decision-making
• No discussion about no treatment
• Limited reference to areas of
uncertainty




High • Support for shared decision-making
• Information is well-balanced
• Relevant information
• Clear references
• Little discussion about the impact
of treatment on QoL
Skin Cancer Cancer.Net High • Clear layout and signposting
• References shared decision-making
• Includes information on palliative care
• Good description of treatments
• No references
• No discussion about no treatment
Squamous Cell Carcinoma The Christie Low • Clear layout of sections
• Provides an overview of treatment
• No specifics about treatment
including benefits and risks
• No discussion about shared
decision-making
•Not aimed at an advanced audience
• No references given
Skin Cancer Cancer Research UK Moderate • Provides description of each treatment
• Offers side effects of each treatment
• Provides references
• No discussion of newer treatments
• No discussion about uncertainty or
impact on QoL




DermNet NZ High • Clear references and signposts
• Description of how treatments work
• Discussion of risks and some benefits
to treatments
• Well-balanced and unbalanced




Healthline Moderate • Well balanced information
• Focus on multiple treatments
• Some reference to QoL
• Limited reference to uncertainty
• Could elaborate on treatment side
effects and benefits
Skin Cancer Macmillan Moderate • Additional signposts provided
• Some discussion about body image
• Treatments are well balanced
• Does not discuss newer treatments
• Does not explain risks with
treatment
• No discussion about uncertainty
Squamous Cell Carcinoma of
the Skin
Mayo Clinic Moderate • Signposts and references provided
• Clearly laid out
• Balanced treatment discussions
• Does not discuss risks or no
treatment
• Does not reference newer
treatments
Squamous Cell Carcinoma Memorial Sloan
Kettering
Low • Description of surgery and
radiotherapy
• No discussion of drug therapy
• No references
• No discussion about risk
• No discussion about QoL
Squamous Cell Carcinoma Moffitt Cancer Center Low • Surgical treatments well laid out • No discussion of drug therapy
• No references
• No discussion about risk





Moderate • Good descriptions of each treatment
• Additional signposts
• Patient encouraged to ask questions
and seek a second opinion
• Side effects are not related to
specific treatments
• No discussion about QoL
• No discussion about shared
decision-making
Types of Skin Cancer NYU Langone Moderate • Description of surgery and
radiotherapy
• Some discussion of treatment benefits
• No immunotherapy information
• No discussion about QoL





This review demonstrates a lack of online information avail-
able for patients with high-risk or advanced cSCC.
Information that is available is not always up to date and does
not necessarily provide sufficient focus on the advanced set-
ting. Given the overall absence of signposting to reliable in-
formation available to these patients, it is concerning that the
disease profile was not prominent evenwithin repositories that
have become trusted sources of information.
This process has demonstrated the trade-off that patients
face when searching for information about their condition.
The broader search terms returned a wide array of informa-
tion, but this was often lacking focus for the advanced or high-
risk setting. However, more specific searches returned far too
technical information. Searches 1–4 returned a large number
of academic and clinical resources, particularly when using
‘advanced’ or ‘high risk’ terminology. Due to health literacy
levels within the population, these are not necessarily appro-
priate resources. In fact, as a primary source of information
available, these could be harmful or fear provoking due to the
discussion around morbidity and mortality [38]. Patients will
often use multiple websites to corroborate information, but
they would need to use a mix of broad and targeted terms,
as demonstrated here, for a better picture of the high-risk and
advanced landscape [17].
A further area of confusion is the ambiguous language used
when referring to high-risk and advanced disease. The words
used, and their accompanying descriptions, differed by site.
Those sites that are recognizable to patients, e.g. Macmillan
and CRUK, did not use the terms at all. This may leave patients
feeling unsure about the information they have previously re-
ceived, either from their medical team or other websites.
This ambiguity is further compounded for UK patients as
the majority of information was aimed at a US audience.
While the information is still broadly relevant for patients
globally, there are some nuances which are important for a
UK setting. For example, conversations about insurance and
care pathways do not necessarily translate. Additionally, the
approach to care carries cultural nuance which may come
across as inappropriate [38]. A prominent area of difference
is that of the initial referral and then later care pathways.
Patients within the UKmay follow a different referral pathway
as opposed to a patient within a private care system. Due to the
lack of UK specific sources, these differences were poorly
outlined. Research suggests non-metastatic patients struggle
with informational needs with very little attention paid to the
metastatic or high-risk setting [10]. Understanding the care
pathway is one such area where patients need information
and signposting.
The range of discern scores demonstrates the variability in
the quality of information available. The majority of pages did
not provide high quality information for patients to then use to
make informed decisions. While this tool does not allow for
assessments of accuracy, we did not find that any pages were
providing biased or inaccurate information. Our primary con-
cern was the omission of detail. For example, while all sites
had been updated within the past 5 years to meet our inclusion
criteria, they did not all contain the most current information
about treatment, namely advances in immunotherapy. There
were also few references to the impact treatments may have on
quality of life, an area that is rarely addressed in the literature
but so pertinent for patient decision-making [10].
Limitations
Inherent to this type of study is that searches will change over
time, and our results will differ depending on individual
search history and geographic location. However, by adding
a repeat search run by a second researcher, we aim to present
results which are representative of those a patient may find.
That variability increases with broader search terms so these
returns are more susceptible to variance. Future studies could
replicate this form of methodology with input from patient
Table 2 (continued)
Resource name Author Overall
DISCERN
score





Low • Various treatment options are
discussed
• Treatment benefits and risks are
not discussed with detail
• Areas of uncertainty are not
discussed
• References are not provided
• No discussion about QoL
Squamous Cell Skin Cancer Wikipedia Moderate • Relevant content
• Well balanced
• Treatment details included
• No discussion about QoL
• No discussion about uncertainty
• No discussion about shared
decision-making
Support Care Cancer
groups as to the most used search terms. Different search
engines could also be used, e.g. Bing, again in line with pa-
tient preference.
Conclusion
The searches presented here demonstrate a need to ensure
online information for patients with either high-risk or ad-
vanced cSCC is accessible, robust, accurate and written in
patient friendly language. This patient group represents a
smaller cohort amongst the cancer population but their infor-
mational needs are not negligible. With variability on termi-
nology, care pathways and relevance, patientsmay be left with
more questions than answers. In an age where more and more
individuals with cancer turn to the Internet for additional sup-
port, further developmental work is needed to tailor appropri-
ate information resources and target this directly to patients.
Practice implications
To address this gap, further work could be undertaken by both
by the clinical teams and charitable groups. Teams could sign-
post patients to reliable online information that contains the
appropriate detail about the advanced or high-risk setting.
While we found hospital-based information, this often only
alluded to disease progression without further details. These
resources could be expanded upon and made available online.
Teams should also be aware of what information is currently
available to patients as a way of pre-empting questions which
may arise. There may be confusion, for example, with mela-
noma and how treatments differ. By understanding the current
online landscape, clinics could then equip patients with key
terms to search for or avoid.
Further work could also be undertaken by websites to en-
sure their information is current with clear guidance on path-
ways and treatments.
A better understanding of the patient experience in this
setting, via qualitative methods, would provide a lived expe-
rience understanding of how best to produce materials and
what information is needed.
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